Who We Are

• CEO and Board Member of BioDelivery Sciences (NASDAQ: BDSI)
• SVP of Allergan – leading several multi-billion dollar divisions
• Chief Marketing Officer and Member Company Management Team – Organon Biosciences
• Executive positions with top tier companies including Bayer, BMS, and Pfizer
• MBA Columbia Business School
• BSE University of Pennsylvania

• Internationally recognized thought leader in areas of perioperative and pain medicines, drug development and regulatory affairs
• Highly published in top tier journals
• Frequent scientific advisor for public and private companies
• Serial entrepreneur, started more than 20 companies
• Johns Hopkins School of Medicine
• Georgetown School of Medicine – residency

Former member of Eli Lilly’s executive committee leading Corporate Strategy and Business Development. Prior roles over a career spanning nearly three decades included president of US operations, various leadership positions in international regions and president of the women’s health franchise.

• Eli Lilly & Co
• Board Member:
  • Horizon Therapeutics
  • Amag Pharma.
  • Intercept Pharma.
  • Collegium Pharma.

30 yrs of experience as a buy-side analyst, portfolio manager, private equity investor and investment banker. Currently focuses on providing CEOs and CFOs with strategic advice on key investor issues.  Former Board member of The Medicines Co. and Vaxart. MBA Stanford School of Business, BA Yale University.

• LifeSci Advisors
• Principal Capital
• Warburg Pincus
• Bear Stearns & Co (now JPM)

20 yrs experience in corporate finance and investment analysis.  Currently co-Chief Investment Officer for public equity investing, with a focus on small cap growth companies.  Prior experience in financial positions in the pharmaceutical industry.  MBA Lehigh University, BAA Wharton, University of Pennsylvania.

• Ashford Capital Management
• Merck & Co.

President of National Spine and Pain Centers, the nation’s largest MSO serving interventional pain management practices, and enterprise of over 1,000 employees. Highly sought after pharmaceutical and medical device company consultant and scientific advisor whose clients have included Abbott, Medtronic, and Collegium among many others. Early advisor in the formation of Axsome Therapeutics (NASDAQ: AXSM) and a member of its board of directors since 2014.  Graduate of Wesleyan University and received his medical degree from Johns Hopkins University School of Medicine.  Dr. Coleman is also a Diplomat of the American Board of Anesthesiology.

World renowned expert in areas of anesthesia and pain and advisor to top regulatory agencies. Founder and Head of Anesthesia & Pain Research Unit at Leiden University. Member of several editorial boards and has published 100s of articles in peer reviewed journals. Professor of Anesthesiology at Leiden University Medical Center.

Accomplished international executive with over 20 years experience in the pharma industry. Former Head of Pharmaco-kinetics at Grünenthal GmbH and Vice President TRF Business at Grünenthal USA, Inc. Frequent presenter on abuse prevention of prescription drugs. Former Head Search & Evaluation at Aquestive Therapeutics.

Seasoned healthcare executive with 20+ years of experience, spanning academia, industry and management consulting. Established TrueNorth Lifesciences. Served as a senior principal in the pharma/ medical device consulting practice within IMS Health. MD, Weill Cornell Medical College, MBA Wharton School of Business, M.Sc. Harvard School of Public Health

Internationally renowned scientist and key opinion leader in pain pathways and analgesics.  Over 30 years industry, academia and  government experience in engineering and pharmacology.  Former team co-leader for analgesics drug discovery at Johnson & Johnson.  Currently affiliated with University of Arizona College of Pharmacy and Temple School of Pharmacy

Practicing emergency medicine specialist with experience treating substance abuse and COVID patients at the largest provider of healthcare in NY State, Northwell Health.  Serves as the Medicine Lead for both the Opiate Task Force and Sepsis Task Force.  Research experience at multiple institutions including Northwell Health, Cornell-Presbyterian Hospital, and University of Medicine and Dentistry of New Jersey

Distinguished leader in anesthesiology working to define best-practice. Chairman of the Department of Anesthesiology at Stoney Brook Medicine and former faculty at the Duke Clinical Research Institute.  Founding President of the American Society of Enhanced Recovery (ASER) and dedicated to improving perioperative care through his role in establishing Enhanced Recovery After Surgery (ERAS) programs.

20+ years of experience in the development of biophysical and pharmacological interventions targeted primarily at critical care pulmonary function and attenuation of ventilator-induced lung injury. Has established and led clinical development globally for the introduction of disruptive medical technologies, including the creation of a new standard of care and playing a significant scientific role in the path to an IPO.  Prior roles with Vixiar Medical, Vapotherm and Nemours.

Over 25 years of experience in the pharmaceutical industry, focusing primarily on Clinical Development and Medical Affairs.  Expertise across multiple therapeutic areas including endocrinology, migraine, neurology, obesity, pain, respiratory, sleep and urology . Prior roles with Currax Pharmaceuticals, Synchrony Healthcare, Nuvo Research, Endo Pharmaceuticals, GlaxoSmithKline.

More than 30 years experience with CMC (Chemistry, Manufacturing and Controls), Analytical and Pharmaceutical Development for early development through NDA/BLA submission as well as for marketed products.  Prior roles with Endo Pharmaceuticals, Johnson & Johnson and DuPont.

Senior pharmaceutical executive with 20+ years’ experience, holding a wide range of commercial leadership roles in sales, marketing, and operations.. Proven ability to thrive in entrepreneurial business environments which include successful establishment of multiple biopharmaceutical organizations. Served as key contributor in the selling and acquisition of commercial entities and assets including negotiations to secure ENA001.

Research professional with a background in early phase clinical studies from both the clinical site and CRO side. Experienced in clinical operations, regulatory compliance, and data management. Earned her MPH at Boston University with a concentration in Epidemiology and Biostatistics and minor in Global Health.